List (MB102008) 2009

NCT00263276

1 Treatments

Studied treatment one of five dapagliflozin doses

Control treatment placebo

Concomittant treatments -

2 Patients

Patients type 2 diabetic patients

Inclusion criteria drug-naive type 2 diabetic patients, aged 18–79 years, with A1C ≥7% and ≤10%.

Exclusion criteria -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>stroke</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References
